Skip to main content
The Oncologist logoLink to The Oncologist
. 2013 Jun;18(6):775. doi: 10.1634/theoncologist.2012-0478erratum

Perspectives on Treatment of Metastatic Castration-Resistant Prostate Cancer

Axel S Merseburger, Joaquim Bellmunt, Cheryl Jenkins, Chris Parker, John M Fitzpatrick, On Behalf of the European Treatment Practices Group
PMCID: PMC4063407

The Oncologist 2013;18:558-567; doi:10.1634/theoncologist.2012-0478

Due to a production error, figure 2 was misprinted. The corrected figure appears below. The publisher regrets this error.

Figure 2.

Figure 2.

Current and possible future sequencing of drugs in castration-resistant prostate cancer in Europe. Abbreviations: GNRH, gonadotropin-releasing hormone; LHRH, luteinizing hormone-releasing hormone; mCRPC, metastatic castration-resistant prostate cancer.


Articles from The Oncologist are provided here courtesy of Oxford University Press

RESOURCES